• Thurs news: GSK inks 2nd neuro pact in weeks. Teva episodic migraine trial. FDA clears AZ’s Imfinzi for aggressive lung cancer. Novartis fails to block generic Entresto. Nuvig gets immune drug funding. See more on our front page

POC Ultrasound













Don’t let the charade of the IPO fool you. This isn’t the place to be. POC is the leftover division (regardless of what they tell you about R&D). The products are not great and the management team is terrible. You will spend more time CYA and trying not to get stepped on and stabbed in the back for about 120k.
 






Don’t let the charade of the IPO fool you. This isn’t the place to be. POC is the leftover division (regardless of what they tell you about R&D). The products are not great and the management team is terrible. You will spend more time CYA and trying not to get stepped on and stabbed in the back for about 120k.


Will GE sell this division off?